Overview
MYMETICS Corporation
Mymetics likes to be on the ground floor of vaccine development. The company holds a portfolio of early-stage vaccines being developed to treat HIV, malaria, herpes, and other viruses. Its key technology uses lipid-like virosomes to carry a vaccine's active ingredients. The development-stage biotech has built its portfolio up through acquisitions, and hopes it can attract a major pharmaceutical partner once it has advanced a drug candidate through
...
Read More early stage clinical trials. Mymetics conducts its clinical testing in Europe and Africa. Its research and development activities take place at its facilities in Switzerland, where it also secures its funding from wealthy individuals.
Read Less
Read More early stage clinical trials. Mymetics conducts its clinical testing in Europe and Africa. Its research and development activities take place at its facilities in Switzerland, where it also secures its funding from wealthy individuals.
Read Less
Ernst Lübke
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Estimated
?
Estimated
$3,388
Actual
$7
?
?
OTC:MYMX
Contacts
Get in Touch with 2 Principals*
-
Ernst LübkeManaging Director and Financial Manager
-
Contact 2?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2023 (12 month period) in USD
Annual Revenue
$3,388
USD
Modelled
1 USD = 0.8855 CHF
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net Operating Cash | -$2 | -$2 | -$2 |
| Net Investing Cash | -$0 | -$0 | -$0 |
| Net Financing Cash | $2 | $1 | $2 |
| Net Change in Cash | -$0 | -$1 | $0 |
| Cash at Beginning of Period | $1 | $1 | $1 |
| Cash at End of Period | $0 | $1 | $1 |
| Capital Expenditure | -$0 | -$0 | -$0 |
| Assets (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $0 | $1 | $1 |
| Accounts Receivable | $0 | $0 | $0 |
| Inventories | $ | $ | $ |
| Other Current Assets | $0 | $0 | $0 |
| Asset Summary | |||
| Total Current Assets | $1 | $1 | $1 |
| Tangible Fixed Assets | $0 | $0 | $0 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $7 | $8 | $8 |
| Liabilities (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $0 | $0 |
| Short-Term Debt | $81 | $76 | $71 |
| Other Current Liabilities | $0 | $0 | $0 |
| Liability Summary | |||
| Total Current Liabilities | $81 | $76 | $71 |
| Long-Term Debt | $0 | $0 | $0 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $82 | $76 | $72 |
| Stakeholder's Equity (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Equity | |||
| Common Stock | $3 | $3 | $3 |
| Retained Earnings | -$116 | -$110 | -$105 |
| Equity Summary | |||
| Total Equity | -$73 | -$68 | -$63 |
| Shares Outstanding | 151,878 | 151,878 | 151,878 |